Sava Infond D.O.O. Regeneron Pharmaceuticals, Inc. Transaction History
Sava Infond D.O.O.
- $566 Billion
- Q4 2024
A detailed history of Sava Infond D.O.O. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Sava Infond D.O.O. holds 690 shares of REGN stock, worth $459,167. This represents 0.09% of its overall portfolio holdings.
Number of Shares
690Holding current value
$459,167% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,486Shares Held
83.9MCall Options Held
1.29MPut Options Held
1.47M-
Vanguard Group Inc Valley Forge, PA9.29MShares$6.18 Billion0.12% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$5.62 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.06MShares$4.7 Billion0.41% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.26 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$2.86 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $71.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...